Free Newsletter
MedImmune: Vaccine ready to go at month's end
MedImmune, which began clinical trials for its swine flu vaccine last month, says the inhaled vaccine could be ready by the end of September. The AstraZeneca subsidiary is now waiting on the FDA to review its safety data. "There are no red flags there," Dr. Raburn Mallory told Reuters. "We think we can have 5 million doses ready to distribute at the end of September." Once it gets the greenlight, MedImmune says it will begin shipping the nasal spray vaccine to the U.S. government to fulfill its $90 million contract. Article
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
More Research Reports >>
SHARE
WITH: